Departments

Prima pagina »  Research  » 

INFLAMMATION

Inflammation Laboratory

Research Interest:

Our research is centered on understanding the mechanisms of cell-to-cell communication and the regulation of inflammation at various post-transcriptional levels of gene expression. We explore these processes across a range of cardiovascular in vivo and in vitro models, including atherosclerosis, myocardial infarction, diabetes, cardiac fibrosis, and valvular pathology.

Main Research Topics:

1. Role of immune cells in cardiac fibrosis.
2. Communication between immune cells and vascular cells in cardiovascular pathologies.
3. Neutrophils, NET-osis, and fibroblast to myofibroblast transition.
4. Communication between monocytes and valve endothelial cells in aortic valve disease associated with diabetes.
5. miR-210 modeling in the monocyte/macrophage lineage in the context of MI.

Our Team:

Contact us:

Elena Butoi, Head of Inflammation Department (CV-link)

elena.dragomir@icbp.ro

Monica Ţucureanu, Lab. PI (CV-link)

monica.pirvulescu@icbp.ro

Previous Grants:

1. 2022-2024: PN-III-P1-1.1-PD-2021-0498 – “Impact of high glucose in valvular endothelial cells-monocyte crosstalk: molecular signatures and role in early valvular dysfunction” - VALDYSIGN

2. 2020-2023: ERA-NET NEURON Call for Joint Transnational Research Projects – “Stroke risk prediction in atherosclerosis measuring circulating complement system proteins” - STATEMENT

3. 2020-2022: PN-III-P2-2.1-PED-2019-4906 – “Development and validation of a native cardiac hydrogel for myocardial repair post-infarction” – NAMIGEL

4. 2018-2022: PN-III-P4-ID-PCCF-2016-0172 – “Targeting innate immune mechanisms to improve risk stratification and to identify future therapeutic options in myocardial infarction” – INNATE-MI

5. 2018-2021: PCCDI Complex Project nr. 13 PCCDI/2018 "Intelligent therapies for non-communicable diseases based on controlled release of pharmacological compounds from encapsulated engineered cells and targeted bio nanoparticles" – INTERA

6. 2016-2020: Competitiveness Operational Programme, Priority Axis 1/Action 1.1.4 “Targeted therapies for diabetes-related aortic valve disease” – THERAVALDIS

7. 2015-2017: PN-II-RU-TE-2014-4-0965 – Vascular cell cross-talk, induces specific microRNAs that can be relevant for atherosclerotic plaque rupture, in type 2 diabetes patients – MIRDIATRIX

8. 2011-2016: PN-II-ID-PCE-2011-3 – Molecules and mechanisms involved in cytokine and chemokine-dependent vascular inflammation as targets for novel nano-therapeutic strategies, Exploratory Research Projects – REFINATER

9. 2011-2014: European Innovative RTD Projects Proposals in Nanomedicine EuroNanoMed JTC 2010, FP7,“Nanoparticles designed to target chemokine-related inflammatory processes in vascular diseases and cancer metastasis and implementation of a biosensor to diagnose these disorders” – NANODIATER

Recent Results

Transcriptional profiling and functional analysis of N1-proinflammatory and N2 – anti-inflammatory neutrophils; immunomodulatory effect of S100A9-blockade on the pro-inflammatory N1.

citeste mai mult

LIPIDOMICS

citeste mai mult

Medical and Pharmaceutical Bionanotechnologies

citeste mai mult

PATHOPHYSIOLOGY AND CELLULAR PHARMACOLOGY

citeste mai mult

PROTEOMICS

citeste mai mult